Skip to main content

Table 1 Baseline characteristics of the included studies in this meta-analysis

From: Effectiveness of early rhythm control in improving clinical outcomes in patients with atrial fibrillation: a systematic review and meta-analysis

Studies (author-year)

Study design

Data source

Inclusion period (y)

AF population for analysis

Sample size (N)

Early rhythm control (N[%])

Age (y)a

Females (%)a

Follow-up time (y)

Kirchhof-2020 [8]

RCT

EAST-AFNET 4

2011-2016

AF diagnosed ≤ 12 months before enrollment

2789

1395 (50.0)

71.0

46.2

5.1

Blomström-2020 [11]

Post hoc analysis of RCT

ATHENA

2005-2006

AF diagnosed ≤ 3 months before enrollment

1296

670 (51.7)

72.5

72.0

NA

Yang-2021 [12]

Post hoc analysis of RCT

AFFIRM

1995-2002

AF diagnosed ≤ 6 months before enrollment

2526

1269 (50.2)

71.0

38.3

3.5

Proietti-2022 [19]

Observational cohort

ESC-EHRA EORP-AF Long-Term General Registry

2013-2016

AF diagnosed ≤ 12 months before enrollment

3774

2052 (54.4)

69.0

44.1

1.85

Kim-2021 [10]

Observational cohort

National Health Insurance Service of Korea

2011-2015

AF diagnosed ≤ 12 months before enrollment

16323

9246 (56.6)

69.0

47.1

2.1

Chao-2022 [22]

Observational cohort

Taiwan National Health Insurance Research Database

2001-2016

AF diagnosed ≤ 12 months before enrollment

301064

62649 (20.8)

68.3

44.5

5.1

Dickow-2022 [21]

Retrospective cohort

US administrative database

2011-2016

AF diagnosed ≤ 12 months before enrollment

109739

27106 (24.7)

68.9

40.8

2.6

Kany-2022 [20]

Retrospective cohort

UK Biobank database

2006-2010

AF diagnosed ≤ 12 months before enrollment

9691

874 (9.91)

68.0

42.0

4.94a

  1. AF Atrial fibrillation, RCT Randomized controlled trial, EAST-AFNET 4 Early Treatment of Atrial Fibrillation for Stroke Prevention Trial, AFFIRM Atrial Fibrillation Follow-up Investigation of Rhythm Management, GARFIELD-AF Global Anticoagulant Registry in the FIELD-AF, ATHENA A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death from any Cause in Patients with Atrial fibrillation/Atrial Flutter, US United States, UK United Kingdom, y years
  2. aData for patients with an early rhythm control treatment